Xenical Diabetes Risk Reduction Data Added To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche weight loss drug adds data from the XENDOS trial showing ability to delay onset of type 2 diabetes in obese patients with impaired glucose tolerance. Change could help Roche increase reimbursement for Xenical.
You may also be interested in...
GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
GlaxoSmithKline's Consumer Healthcare division will detail the weight-loss therapy, focusing on diabetes risk reduction data recently added to labeling. Xenical was last detailed by Roche in November 2003. The Rx-to-OTC application is planned for mid-year.
GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
GlaxoSmithKline's Consumer Healthcare division will detail the weight-loss therapy, focusing on diabetes risk reduction data recently added to labeling. Xenical was last detailed by Roche in November 2003. The Rx-to-OTC application is planned for mid-year.
Advisory OTCs? GSK Discusses “Third Class” Drug Paradigm, But Xenical Not Included
GSK Consumer Healthcare’s Regnier says firm is discussing pharmacy-only class internally but has yet to take a formal stance on the issue. Any switch of the weight-loss drug orlistat would occur within the existing two-class system, the company says.